Financial Performance - In 2024, the company achieved operating revenue of 1.443 billion, a year-on-year decrease of 6.39% [3] - Net profit attributable to shareholders increased by 12.66% to 55.441 million [3] - The pharmaceutical sector's price adjustments in response to national policies have begun to mitigate the impact of collective procurement [3] Business Segments - The medical device segment has expanded its market presence, covering 80% of provinces and over 50 cities [4] - The South African subsidiary has shown significant growth, leveraging local distribution networks to introduce domestic medical equipment to the African market [4] Research and Development - The company is focusing on innovative drugs, generic drugs, raw materials, and traditional Chinese medicine, with a dedicated R&D team of 120 [6] - Key projects include clinical trials for drugs targeting Alzheimer's and other serious conditions, with FDA approvals for several products [6] Investor Relations - The company emphasizes transparency and interaction in investor relations, utilizing various communication channels to ensure effective information dissemination [7] - Future plans include enhancing digital capabilities and conducting scenario-based roadshows to strengthen investor understanding of the company's growth logic [7]

一年前，施跃和他的团队做了一个国内基金圈少有人敢于尝试的事情。 2024年3月14日下午，和谐汇一的官方公众号发表文章，对即将开启百亿美金蓝海市场的NASH（非酒精性脂肪肝）赛道进行了详细介绍[1]。业内很多人都知道当 日晚间，FDA即将公布对首款NASH治疗药物Rezdiffra的评审，如果最终获批，将会创造该领域的历史性突破。 在 FDA 公告前，和谐汇一敢于对这项突破性技术做出前瞻预判，在小圈子里引起了很多赞叹。 事实上，这已经不是和谐汇一医药团队第一次做出这种判断。无论是港股上市的创新药出海龙头，还是因为获得了某款国产创新药海外授权而涨幅超十倍的美股 明星公司，和谐汇一的买入点常常都是市场还没有形成"一致性预期"的时候。 对于施跃和医药团队里的其他年轻研究员来说， 他们凭借对医药行业的深入研究和敏锐洞察，以及在投资实践中积累的经验，生动诠释 了"超额收益往往来自于 非共识的正确" 这一理念。 但从理论到实践，"非共识"往往需要一个投资团队投入专注的研究心力，并有果敢的魄力在该出手的时候，坚决出手。 放在整个行业维度，这种认知上的加持、信念上的加码也是一个医药投研团队在过去几年国内医药行业整体低迷的现实 ...